EGFR and non-small cell lung carcinoma: Recent studies have shownthat the development of epidermal growth factor receptor(EGFR)-targeted tyrosine kinase inhibitors causes a significantadvances in patients with tumors harboring EGFR mutations.Thus, about 50% of Asian patients with NSCLC have EGFRmutations [2].